No Data
No Data
Sichuan Hebang Biotechnology (603077.SH): has begun the preparatory work for the early exploration of the AEV company's gold mine.
On September 18, Hexinbiotech (603077.SH) stated on the investor interaction platform that, considering the company's sustainable and high-quality development global strategy requirements, combined with the current company's mining sector profit contribution, the company plans to extend upstream resources chain to seek investment opportunities and increase mineral resource reserves. The company's controlling stake in the Australian AEV company owns mining rights to approximately 1,724 square kilometers of gold mine exploration area, and the company has begun preparations for the preliminary work of AEV company's gold mine exploration.
Individual Investors Among Sichuan Hebang Biotechnology Corporation Limited's (SHSE:603077) Largest Stockholders and Were Hit After Last Week's 3.4% Price Drop
Sichuan Hebang Biotechnology (603077.SH): has repurchased 0.48% of the shares.
On September 3rd, GeLonghui announced that as of August 31, 2024, the company has cumulatively repurchased 42,498,460 shares through the Shanghai Stock Exchange trading system with a proportion of 0.48% of the total share capital. The highest purchase price was 1.69 yuan/share, the lowest purchase price was 1.64 yuan/share, and the total amount paid was 70,665,957.82 yuan.
Hebang Biotech 2024 Semi-Annual Report
Summary of Hebang Biotech\'s 2024 Semi-Annual Report
Investors in Sichuan Hebang Biotechnology (SHSE:603077) Have Unfortunately Lost 30% Over the Last Three Years
No Data
No Data